3,4-dihydro-1H-benzo[1,2,6]thiadiazine 2,2-dioxide | 33853-77-9

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 3,4-dihydro-1H-benzo[1,2,6]thiadiazine 2,2-dioxide
• 英文别名: 3,4-Dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxide；3,4-Dihydro-2,1,3-benzothiadiazin-2,2-dioxid；1H-2,1,3-Benzothiadiazine, 3,4-dihydro-, 2,2-dioxide；3,4-dihydro-1H-2λ6,1,3-benzothiadiazine 2,2-dioxide
• CAS: 33853-77-9
• 化学式: C₇H₈N₂O₂S
• 分子量: 184.219
• InChiKey: HJOCDLYJUZLBLI-UHFFFAOYSA-N

物化性质

• 熔点：
  183-185 °C
• 沸点：
  335.2±45.0 °C(Predicted)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-1H-benzo[1,2,6]thiadiazine 2,2-dioxide 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-(1-benzyl-2,2-dioxo-1,4-dihydro-2H-2λ6-benzo[1,2,6]thiadiazin-3-yl)-ethanol
  参考文献：
  名称：

  1H-2.1.3-Benzothiadiazin-2.2-dioxide Cyclische und bicyclische Sulfamide, 2. Mitt.

  摘要：

  DOI：

  10.1007/bf00909932
• 作为产物：
  描述：

  2-氨基苄胺 生成 3,4-dihydro-1H-benzo[1,2,6]thiadiazine 2,2-dioxide
  参考文献：
  名称：

  1H-2.1.3-Benzothiadiazin-2.2-dioxide Cyclische und bicyclische Sulfamide, 2. Mitt.

  摘要：

  DOI：

  10.1007/bf00909932

文献信息

• [EN] 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM<br/>[FR] DERIVES DE 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE ET DERIVES DE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXYDE ET DE 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE RESPECTIFS, UTILISES COMME MODULATEURS DU RECEPTEUR DE LA 5-HYDROXYTRYPTAMINE (5-HT) POUR LE TRAITEMENT D'AFFECTIONS DU SYSTEME NERVEUX CENTRAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005067933A1

  公开（公告）日：2005-07-28

  The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z is -(CRaRb)r- or -SO2-, wherein r is from 0 to 2 and each of Ra and Rb is independently hydrogen or alkyl; X is CH or N; R2 is optionally substituted aryl or optionally substituted heteroaryl; preferably R2 is aryl, and more preferably phenyl optionally substituted by one or more trifluoromethyl, halo, cyano, C1-C6 alkyl or C1-C6 alkoxy; A is -NR3- or -O- wherein R3 is: hydrogen; alkyl, acyl, amidoalkyl, hydroxyalkyl or alkoxyalkyl; the other substituents are defined in the claims. The compounds are modulators of the 5-hydroxytryptamine receptor and are useful for the treatment of diseases of the central nervous system such as psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, food uptake disorders, and Huntington’s disease.

  该发明涉及式(I)的取代喹唑啉酮化合物或其药学上可接受的盐，其中Y为C或S；当Y为C时，m为1，当Y为S时，m为2；n为1或2；p为0到3；q为1到3；Z为-(CRaRb)r-或-SO2-，其中r为0到2，Ra和Rb各自独立地为氢或烷基；X为CH或N；R2为可选择地取代的芳基或可选择地取代的杂环烷基；优选R2为芳基，更优选为苯基，可选地取代为一个或多个三氟甲基，卤素，氰基，C1-C6烷基或C1-C6烷氧基；A为-NR3-或-O-，其中R3为：氢；烷基，酰基，酰胺烷基，羟基烷基或烷氧基烷基；其他取代基在权利要求中定义。这些化合物是5-羟色胺受体的调节剂，可用于治疗中枢神经系统疾病，如精神病、精神分裂症、躁郁症、神经系统疾病、记忆障碍、注意力缺陷障碍、帕金森病、肌萎缩侧索硬化症、阿尔茨海默病、摄食障碍和亨廷顿病。
• New Compounds
  申请人：PRIEPKE Henning

  公开号：US20110263556A1

  公开（公告）日：2011-10-27

  This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E 2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R 1 , R 2 , R 7 , R a , R b , Q 3 , Q 4 , Q 6 , Z 2 , Z 4 , Z 5 , Z 6 and W have meanings given in the description.

  本发明涉及式I的化合物，它们作为微粒体前列腺素E2合酶-1（mPGES-1）的抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病和相关情况（如炎症性/疼痛性疼痛）的药物的用途。A、M、R1、R2、R7、Ra、Rb、Q3、Q4、Q6、Z2、Z4、Z5、Z6和W在描述中给出了它们的含义。
• Basicity of nitrogen–sulphur(<scp>VI</scp>) compounds. Part 6. Ionization of NN′-di-and N-mono-substituted sulphamides and dihydro-2,1,3-benzothiadiazoline and benzothiadiazine 2,2-dioxides (cyclic sulphamides)
  作者：Padraig O. Burke、Séan D. McDermott、Thomas J. Hannigan、William J. Spillane

  DOI：10.1039/p29840001851

  日期：——

  tri-substituted sulphamides have been synthesised and their ionization equilibria in base (Schemes 1–3) have been studied. Many of the sulphamides are new materials. The pKa values obtained for each series have been correlated in Hammett and Taft plots. The Hammett ρ values obtained for the ionization of the proximate hydrogen are ca. 2.3. The Taft ρ* value obtained for ionization of the ‘remoter’

  已合成了36个二取代的，单取代的和两个三取代的磺酰胺，并研究了它们在碱中的电离平衡（方案1-3）。许多磺酰胺是新材料。在Hammett和Taft图中，已将每个系列获得的p K a值关联起来。对于邻近氢的电离获得的哈米特ρ值约为。2.3。用于“远程”氢离子化获得的Taftρ*值为1.68。六元环状磺酰胺比其无环类似物的酸性大约高出约2。2.5 p ķ一个单元和五元环sulphamides是CA。4 p K a单元比模型开放链对应单元酸性更高。硫d-轨道参与和环应变被认为是这种“增强酸”作用的可能来源。
• Facile synthesis of 4-substituted 3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxides
  作者：Chai-Ho Lee、Guo Fan Jin、Hyun Wha Lim、Eun Hye Yang、Jong-Dae Lee、Hiroyuki Nakamura、Hyun Seung Ban、Sang Ook Kang

  DOI：10.1002/hc.20670

  日期：——

  A new method for the preparation of 4-substituted 3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxides is described. Treatment of t-butyl N-phenylsulfamoylcarbamate derivatives (1) with different aldehydes afforded the corresponding intramolecular cyclized products 2 under trifluoroacetic acid conditions. © 2011 Wiley Periodicals, Inc. Heteroatom Chem 22:192–197, 2011; View this article online at wileyonlinelibrary

  描述了一种制备 4-取代 3,4-二氢-1H-2,1,3-苯并噻二嗪 2,2-二氧化物的新方法。在三氟乙酸条件下，用不同的醛处理叔丁基 N-苯基氨磺酰基氨基甲酸酯衍生物 (1) 得到相应的分子内环化产物 2。© 2011 Wiley Periodicals, Inc. 杂原子化学 22:192–197, 2011; 在 wileyonlinelibrary.com 上在线查看这篇文章。DOI 10.1002/hc.20670
• Preventives/remedies for urinary disturbance
  申请人：Ishihara Yuji

  公开号：US20050197362A1

  公开（公告）日：2005-09-08

  Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

  具有乙酰胆碱酯酶抑制作用和α1拮抗作用的化合物的预防/治疗措施，可以显著改善膀胱的尿液功能（即改善尿流率和排尿效率的效果），而不影响尿压或血压。